S 1522

A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

Congress: 118 (2023–2025, Ended)
Chamber: Senate
Policy Area: Health
Introduced: May 10, 2023
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 10, 2023)
Official Text: https://www.congress.gov/bill/118th-congress/senate-bill/1522

Sponsor

Name: Sen. Marshall, Roger [R-KS]
Party: Republican • **State:** KS • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 10, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of May 10, 2023)

This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

Actions Timeline

- **May 10, 2023:** Introduced in Senate
- **May 10, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.